Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis.

Employee Rating

1.0More
TypePublic
HQWarren, US
Founded2009
Size (employees)20 (est)-9%
Websitebellerophon.com
Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Bellerophon Therapeutics

Jonathan Peacock

Jonathan Peacock

Chairman
Assaf Korner

Assaf Korner

CFO
Martin Dekker

Martin Dekker

Vice President, Engineering and Manufacturing
Amy Edmonds

Amy Edmonds

Vice President, Clinical Operations and Administration
Show more

Bellerophon Therapeutics Office Locations

Bellerophon Therapeutics has an office in Warren
Warren, (HQ)
302 184 Liberty Corner Rd
Show all (1)
Report incorrect company information

Bellerophon Therapeutics Financials and Metrics

Bellerophon Therapeutics Revenue

USD

Net income (Q2, 2018)

(11.5m)

EBIT (Q2, 2018)

(7.9m)

Market capitalization (4-Dec-2018)

62.2m

Closing stock price (4-Dec-2018)

1.1

Cash (30-Jun-2018)

23.4m
Bellerophon Therapeutics's current market capitalization is $62.2 m.
Annual
USDFY, 2015FY, 2016FY, 2017

General and administrative expense

14.9m7.1m6.7m

R&D expense

33.4m16.7m17.9m

Operating expense total

48.2m23.8m24.6m

EBIT

(46.6m)(23.8m)(24.6m)
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

4.6m3.4m4.3m2.0m1.2m1.7m1.4m3.1m1.7m2.1m2.1m

R&D expense

9.5m8.4m7.1m5.1m4.0m2.5m3.3m8.0m4.4m6.4m5.8m

Operating expense total

14.1m11.9m11.4m7.1m5.2m4.2m4.8m11.1m6.2m8.5m7.9m

EBIT

(12.9m)(11.6m)(11.2m)(7.1m)(5.2m)(4.2m)(4.8m)(11.1m)(6.2m)(8.5m)(7.9m)
Annual
USDFY, 2015FY, 2016FY, 2017

Cash

6.3m14.5m28.8m

Current Assets

29.5m26.5m35.6m

PP&E

1.8m1.4m1.0m

Total Assets

38.4m29.7m36.8m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Cash

62.9m48.5m23.9m1.3m1.3m3.9m13.5m11.0m32.3m28.4m23.4m

Current Assets

73.6m60.9m46.9m23.1m18.6m17.5m23.2m20.4m39.4m34.8m28.8m

PP&E

1.6m1.5m1.8m1.7m1.6m1.5m1.3m1.2m1.1m935.0k845.0k

Total Assets

75.2m62.4m49.2m31.2m26.3m22.8m25.8m22.4m40.9m35.9m29.8m
Annual
USDFY, 2015FY, 2016

Net Income

(46.5m)(23.8m)

Depreciation and Amortization

(377.0k)(400.0k)

Cash From Operating Activities

(46.3m)(17.2m)

Cash From Investing Activities

(18.3m)12.2m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

Net Income

(12.9m)(24.5m)(35.6m)(7.1m)(5.1m)(4.2m)(19.1m)(23.1m)(30.7m)4.1m(7.4m)

Depreciation and Amortization

183.0k273.0k104.0k192.0k283.0k91.0k181.0k

Accounts Payable

659.0k966.0k934.0k641.0k2.0m2.2m3.9m(796.0k)(552.0k)

Cash From Operating Activities

(18.0m)(29.0m)(6.7m)(8.2m)(11.2m)(444.0k)(6.1m)
USDY, 2018

Financial Leverage

-3.8 x
Show all financial metrics
Report incorrect company information

Bellerophon Therapeutics Blogs

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start blogging! The post Hello world! appeared first on bellerophon.

Bellerophon Therapeutics Company Life and Culture

Report incorrect company information

Bellerophon Therapeutics Frequently Asked Questions

  • When was Bellerophon Therapeutics founded?

    Bellerophon Therapeutics was founded in 2009.

  • Who are Bellerophon Therapeutics key executives?

    Bellerophon Therapeutics's key executives are Jonathan Peacock, Assaf Korner and Martin Dekker.

  • How many employees does Bellerophon Therapeutics have?

    Bellerophon Therapeutics has 20 employees.

  • Who are Bellerophon Therapeutics competitors?

    Competitors of Bellerophon Therapeutics include SciBac, Cellestia Biotech and Alvine Pharmaceuticals.

  • Where is Bellerophon Therapeutics headquarters?

    Bellerophon Therapeutics headquarters is located at 302 184 Liberty Corner Rd, Warren.

  • Where are Bellerophon Therapeutics offices?

    Bellerophon Therapeutics has an office in Warren.

  • How many offices does Bellerophon Therapeutics have?

    Bellerophon Therapeutics has 1 office.